<code id='1562026F4E'></code><style id='1562026F4E'></style>
    • <acronym id='1562026F4E'></acronym>
      <center id='1562026F4E'><center id='1562026F4E'><tfoot id='1562026F4E'></tfoot></center><abbr id='1562026F4E'><dir id='1562026F4E'><tfoot id='1562026F4E'></tfoot><noframes id='1562026F4E'>

    • <optgroup id='1562026F4E'><strike id='1562026F4E'><sup id='1562026F4E'></sup></strike><code id='1562026F4E'></code></optgroup>
        1. <b id='1562026F4E'><label id='1562026F4E'><select id='1562026F4E'><dt id='1562026F4E'><span id='1562026F4E'></span></dt></select></label></b><u id='1562026F4E'></u>
          <i id='1562026F4E'><strike id='1562026F4E'><tt id='1562026F4E'><pre id='1562026F4E'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:5285
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In